Anticancer Activity of Two Novel Hydroxylated Biphenyl Compounds toward Malignant Melanoma Cells.
Antineoplastic Agents
/ chemical synthesis
Apoptosis
/ drug effects
Biphenyl Compounds
/ chemical synthesis
Cell Cycle
/ drug effects
Cell Line, Tumor
Drug Screening Assays, Antitumor
Humans
Melanoma
/ drug therapy
Signal Transduction
/ drug effects
Skin Neoplasms
/ drug therapy
Structure-Activity Relationship
Melanoma, Cutaneous Malignant
apoptosis
curcumin analogs
hydroxylated biphenyl
melanoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
23
04
2021
revised:
17
05
2021
accepted:
18
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Melanoma, the deadliest form of skin cancer, is still one of the most difficult cancers to treat despite recent advances in targeted and immune therapies. About 50% of advanced melanoma do not benefit of such therapies, and novel treatments are requested. Curcumin and its analogs have shown good anticancer properties and are being considered for use in combination with or sequence to recent therapies to improve patient outcomes. Our group previously published the synthesis and anticancer activity characterization of a novel curcumin-related compound against melanoma and neuroblastoma cells (D6). Here, two hydroxylated biphenyl compounds-namely, compounds
Identifiants
pubmed: 34073232
pii: ijms22115636
doi: 10.3390/ijms22115636
pmc: PMC8198844
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Biphenyl Compounds
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Regione Autonoma della Sardegna
ID : BiCoMe development agreement
Organisme : Fase 1 SRL
ID : BiCoMe development agreement
Références
Cancer Treat Res. 2016;167:149-79
pubmed: 26601862
Nat Med. 2021 Feb;27(2):212-224
pubmed: 33574607
J Vis Exp. 2014 Oct 27;(92):e51998
pubmed: 25408172
Int J Mol Sci. 2020 Nov 11;21(22):
pubmed: 33187200
Mol Cancer. 2013 May 04;12:37
pubmed: 23642048
PLoS One. 2015 Mar 05;10(3):e0118702
pubmed: 25742310
BMC Cancer. 2016 May 18;16:317
pubmed: 27192978
Curr Med Chem. 2014;21(2):204-22
pubmed: 23590716
Nutr Metab (Lond). 2019 May 21;16:33
pubmed: 31139235
Tumour Biol. 2013 Apr;34(2):1119-29
pubmed: 23359272
Cancer Treat Res. 2016;167:209-29
pubmed: 26601864
Medicina (Kaunas). 2021 Apr 08;57(4):
pubmed: 33917690
Nat Rev Cancer. 2017 Nov;17(11):692-704
pubmed: 29026206
Eur J Med Chem. 2019 Sep 1;177:76-104
pubmed: 31129455
J Inorg Biochem. 2017 Sep;174:14-24
pubmed: 28558258
Cancer Treat Res. 2016;167:17-49
pubmed: 26601858
Molecules. 2014 Aug 06;19(8):11679-721
pubmed: 25102117
Am Soc Clin Oncol Educ Book. 2018 May 23;38:751-758
pubmed: 30231371
Sci Rep. 2017 Apr 24;7(1):1105
pubmed: 28439094
Br J Cancer. 2015 Jan 20;112(2):217-26
pubmed: 25180764
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
BMC Cancer. 2009 Oct 03;9:352
pubmed: 19799798
Mol Cancer. 2010 Jun 03;9:137
pubmed: 20525240
Exp Dermatol. 2008 Jan;17(1):1-11
pubmed: 18095940
Anticancer Res. 2015 Feb;35(2):645-51
pubmed: 25667441
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Eur J Cancer. 2018 Mar;92:108-118
pubmed: 29395684
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Int J Mol Sci. 2018 May 24;19(6):
pubmed: 29795011
Chem Rev. 2011 Feb 9;111(2):563-639
pubmed: 20939606
Clin Cancer Res. 2003 Aug 15;9(9):3492-502
pubmed: 12960142
Cell Prolif. 2014 Dec;47(6):506-15
pubmed: 25377084
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33037115
ChemMedChem. 2021 Mar 18;16(6):1022-1033
pubmed: 33274847
Cold Spring Harb Protoc. 2018 Jun 1;2018(6):
pubmed: 29858338
Front Oncol. 2015 Aug 10;5:183
pubmed: 26322273
Dermatol Ther. 2019 May;32(3):e12842
pubmed: 30693615
Curr Pharm Biotechnol. 2020;21(11):1006-1015
pubmed: 32133961
Arch Immunol Ther Exp (Warsz). 2005 Jan-Feb;53(1):28-38
pubmed: 15761374
Cancers (Basel). 2021 Jan 09;13(2):
pubmed: 33435389
J Transl Med. 2019 Jul 22;17(1):234
pubmed: 31331337
J Oncol. 2019 Feb 3;2019:5245034
pubmed: 30853982
Transl Oncol. 2017 Dec;10(6):956-975
pubmed: 29078205